



IPO : Gaudium IVF & Women Health Limited

February 2026

Snapshot

Gaudium IVF and Women Health Limited is a Delhi-based fertility and women’s healthcare provider incorporated in March 2015 and converted into a public limited company in October 2024. Headquartered in Janakpuri, New Delhi, the company offers assisted reproductive technology (ART) services including IVF, fertility preservation, and comprehensive gynecology care. Promoted by Dr. Manika Khanna, Dr. Peeyush Khanna, and Vishad Khanna, Gaudium focuses on patient-centric, technology-driven reproductive solutions. The company is undertaking an initial public offering comprising a fresh issue and offer for sale, with proposed listing on BSE and NSE to support growth and expansion plans.

Company Vision

Gaudium IVF and Women Health Limited envisions becoming a leading and trusted fertility and women’s healthcare provider in India and globally, committed to delivering ethical, accessible, and technology-driven reproductive solutions. The company aims to empower individuals and couples with comprehensive, evidence-based fertility treatments supported by advanced medical infrastructure and compassionate care. Its vision is to set new benchmarks in clinical excellence, patient experience, and success rates while expanding its footprint across key markets. By fostering innovation, skilled medical expertise, and transparent practices, Gaudium strives to create hope, nurture families, and contribute meaningfully to the evolving landscape of reproductive healthcare.

Risk Assessment

Gaudium IVF and Women Health Limited has strong growth prospects driven by rising infertility rates, increasing awareness of assisted reproductive technology (ART), and improving affordability of fertility treatments in India. The expanding middle-class population, delayed parenthood trends, and supportive regulatory framework for ART clinics further create favorable industry dynamics. The company plans to leverage its brand reputation, clinical expertise, and technology-enabled services to expand into new geographies and strengthen existing centers. With increasing demand for advanced procedures such as IVF, ICSI, and fertility preservation, Gaudium is well positioned to enhance revenue streams, improve operational scale, and deliver sustainable long-term growth.

Opening Date	Friday, February 20, 2026
Closing Date	Tuesday, February 24, 2026
Price Band	Rs. 75 to Rs. 79 per share
Bid Lot	189 Shares
Face Value	Rs. 5 per share
Issue Size	2,08,86,200 shares (aggregating up to Rs. 165 Cr)
Fresh Issue	1,13,92,500 shares (aggregating up to Rs. 90 Cr)
Offer for Sale	94,93,700 shares (aggregating up to Rs. 75 Cr)
Registrar	Bigshare Services Pvt.Ltd.

Key Financial				
Amount in cr.	30-Sep-25	FY2025	FY2024	FY 2023
Assets	106.62	88.51	51.01	36.63
Total Income	49.75	70.96	48.15	44.26
Profit After Tax	12.51	19.13	10.32	13.53
EBITDA	18.95	28.63	19.27	20.07
NET Worth	58.85	46.30	26.99	22.73
Reserves and Surplus	28.16	15.60	26.00	21.74
Total Borrowing	22.51	18.93	15.73	9.78

Growth Prospects

Gaudium IVF and Women Health Limited faces several risk factors that could impact its growth prospects. The company operates in a highly regulated healthcare environment, and any changes in ART regulations, licensing requirements, or compliance standards may affect operations. Intense competition from established fertility chains and emerging clinics could pressure pricing and margins. Clinical outcomes and success rates significantly influence brand reputation, making quality control critical. Additionally, expansion plans require capital investment and efficient execution, exposing the company to financial and operational risks. Dependence on key medical professionals and economic fluctuations may also influence patient demand and overall performance.